SCHOTT Pharma, a pioneer in pharma drug containment and delivery solutions, broke ground on a new production hub for prefillable glass syringes (PFS) at its site in Lukácsháza, Hungary.
“With this move, we are staying one step ahead in providing high-value solutions to store biologics, vaccines and the latest generation of mRNA-based medications,” said Andreas Reisse, CEO at SCHOTT Pharma. The double-digit million Euro investment is supported by funding from the local government. The capacity increase is scheduled for completion in 2024 and designed to create 120 new jobs.
“With the new production in Lukácsháza, we are adding a second production hub for glass PFS to SCHOTT Pharma’s global manufacturing network,” said Christian Helbig, Vice President for Prefillable Glass Syringes at SCHOTT Pharma. In line with the company’s philosophy of maintaining the highest quality, it will feature fully automated manufacturing processes, cutting-edge machinery, as well as an advanced camera-controlled inspection system.
The high-quality PFS not only offer a stable, long-term storage solution for drugs, but also a safe and convenient delivery system for patients and clinicians. “With our PFS system, we are eliminating almost all drug injection preparation steps and thereby reducing the risk of medical errors and contaminations. This plays a vital role in the safety of health care professionals and patients,” continued Helbig. SCHOTT Pharma offers a broad portfolio of different syringe formats and pre-tested components, such as closures and plungers that pharma companies can choose from.